drugset / Trial / NCT05385068
A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi
Phase 2
Unknown
35 enrolled
Peking Union Medical College Hospital
Zai Lab (Shanghai) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will be an open-label, single-arm, prospective, exploratory phase II trial to investigate the efficacy and safety of niraparib maintenance retreatment in platinum- sensitive recurrent (PSR) epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer).
Timeline
- Start
- 2022-06
- Primary completion
- 2024-03
- Completion
- 2024-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |
| Background | Catequentinib | Small molecule | 10 mg | Oral |